Akari Therapeutics, Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2010
Selling, General & Admin	11.36	13.53	8.08	9.16	8.22	Upgrade
Research & Development	5.45	9.56	9.13	8.82	8.74	Upgrade
Operating Expenses	16.81	23.09	17.21	17.98	16.96	Upgrade
Operating Income	-16.81	-23.09	-17.21	-17.98	-16.96	Upgrade
Other Expense / Income	-6.8	-5.34	0.21	-0.9	-0.12	Upgrade
Pretax Income	-10.01	-17.75	-17.42	-17.08	-16.85	Upgrade
Net Income	-10.01	-17.75	-17.42	-17.08	-16.85	Upgrade
Shares Outstanding (Basic)	9,789	6,243	4,292	3,159	1,831	Upgrade
Shares Outstanding (Diluted)	9,789	6,243	4,292	3,159	1,831	Upgrade
Shares Change	56.79%	45.46%	35.87%	72.53%	18.87%	Upgrade
EPS (Basic)	-	-	-	-20.00	-20.00	Upgrade
EPS (Diluted)	-	-	-	-20.00	-20.00	Upgrade
Free Cash Flow	-16.43	-21.5	-18.85	-16.95	-12.92	Upgrade
Free Cash Flow Per Share	-3.36	-6.89	-8.78	-10.73	-14.11	Upgrade
EBITDA	-10	-17.74	-17.42	-17.07	-16.83	Upgrade
Depreciation & Amortization	0	0	0	0.01	0.02	Upgrade
EBIT	-10.01	-17.75	-17.42	-17.08	-16.85	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).